FDA clears Taro Pharma's Keveyis for rare inherited muscle disorder

• The FDA approves Taro Pharmaceutical Industries' (TARO +0.5%) Keveyis (dichlorphenamide) 50 mg tablets for the treatment of primary hyperkalemic (excess potassium in the blood) and hypokalemic (reduced levels of potassium in the blood) periodic paralysis, a group of rare inherited disorders that are characterized by episodes of extreme muscle weakness during which sufferers are unable to move muscles in the arms and legs for hours or days. The disorder affects ~5,000 Americans.
• The product launch will commence this quarter.